A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 Study) - Abstract

OBJECTIVE: Abiraterone acetate has been approved in >70 countries for chemotherapy-naïve metastatic castration-resistant prostate cancer patients.

Efficacy and safety of abiraterone acetate (1000 mg/once daily) with prednisolone (5 mg/twice daily) in chemotherapy-naïve Japanese patients with metastatic castration-resistant prostate cancer was evaluated.

METHODS: Men, ≥20 years, with prostate-specific antigen levels of ≥5 ng/ml and evidence of progression were enrolled in this Phase 2, multicenter, open-label study. Primary efficacy endpoint was proportion of patients achieving a prostate-specific antigen decline of ≥50% from baseline (prostate-specific antigen response) after 12 week of treatment. Secondary efficacy endpoints and safety were assessed.

RESULTS: A confirmed prostate-specific antigen response was observed in 29/48 (60.4%) patients by week 12; lower limit of two-sided 90% confidence interval was >35% (threshold response rate), demonstrating efficacy of abiraterone acetate. Secondary efficacy endpoints: prostate-specific antigen response rate during treatment period: 62.5%; objective radiographic response, partial response: 4/18 (22.2%) patients; complete response: none; stable disease: 11/18 (61.1%) patients; median percent change in prostate-specific antigen level from baseline at Week 12: -66.62%. Median prostate-specific antigen response duration and progression-free survival were not reached, and median radiographic progression-free survival was 253 days. Of 31/48 (64.6%) patients experienced adverse events of special interest; most common was hepatic function abnormality (37.5%, Grade 3: 10.4%). One Grade 3 hypertension was the only mineralocorticoid adverse event >Grade 1/2.

CONCLUSIONS: Efficacy of abiraterone acetate plus prednisolone was demonstrated by decline in prostate-specific antigen levels with evidence of antitumor activity by radiography in Japanese patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. Abiraterone acetate plus prednisolone had an acceptable safety profile.

Written by:
Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S, Akaza H.   Are you the author?
Division of Oncology and Hematology, National Cancer Center Hospital East, Chiba; Department of Urology, Kinki University Faculty of Medicine, Osaka; Department of Urology, Kitasato University School of Medicine, Kanagawa; Department of Urology, Toho University Sakura Medical Center, Chiba; Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University, Graduate School of Medical and Dental Sciences, Niigata; Department of Urology, Yokohama City University Graduate School of Medicine, Kanagawa; Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama; Janssen Pharmaceutical K.K, Tokyo; Department of Urology, Hamamatsu University School of Medicine, Shizuoka; Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.  

Reference: Jpn J Clin Oncol. 2014 Oct 15. pii: hyu149.
doi: 10.1093/jjco/hyu149


PubMed Abstract
PMID: 25320340

UroToday.com mCRPC Treatment Section